SBIR Phase I: Thermoelectric DNA Sequencer for Mutation Detection

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1141957
Agency Tracking Number: 1141957
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solicitation Year: 2012
Solicitation Topic Code: BC
Solicitation Number: N/A
Small Business Information
1453 E. Los Arboles Drive, Tempe, AZ, 85284-2460
DUNS: 808429927
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Eric Guilbeau
 (480) 229-5818
Business Contact
 Eric Guilbeau
Phone: (480) 229-5818
Research Institution
This Small Business Innovation Research (SBIR) Phase I project proposes to develop a highly innovative, thermoelectric, microfluidic DNA sequencing method for mutation detection (e.g., SNPs) for applications in personalized medicine. The overall objective is to optimize operational parameters and microfluidic device design variables to overcome three factors that limit the accuracy of the sequencing method. To achieve this overall objective, the project will address the following three technical objectives: Technical objective 1, optimize parameters to ensure that all available nucleotide sites are extended during a single nucleotide injection, technical objective 2, optimize parameters to reduce the level of dNTP misincorporation, and technical objective 3, develop improved strategies for sequencing mutations involving homopolymeric regions. Single nucleotide polymorphisms (SNPs) are single base pair variations within the genome that are important indicators of genetic predisposition towards specific diseases. There is a significant medical need and commercial market in the field of personalized medicine for a less expensive, more efficient, simple and sensitive SNP detection assay. Thermoelectric DNA sequencing is a discontinuous innovation, unlike any existing method for sequencing DNA. Despite the high-risk, successful commercialization of thermoelectric sequencing will provide a transformative, inexpensive, simple method for mutation detection. The broader impact/commercial potential of this project, if successful, is in personalized medicine. SNPs are the most abundant class of polymorphism and predispose individuals to specific diseases and influence their response to drugs. Wide-spread screening of the population for genetic mutations (e.g. SNPs) will dramatically decrease health care costs and produce significant positive social impact by enabling the early detection of inherited disease, more effective and timely treatment, and lower mortality and morbidity among the population. Thermoelectric sequencing offers the potential to transform the field of personalized medicine by extending genetic testing into the clinical laboratory and doctor's office. Genetic testing identifies individuals who have predisposition to diseases before the onset of the symptoms. Cancer for example, one of the leading causes of mortality in the United States, causes 558,644 deaths per year. The cost of cancer treatment is estimated to be $104.1 billion per year that adds to the staggering cost of healthcare in the United States. The cost of healthcare in the United States is $2.199 trillion per year that is 16% of the GDP of the country. Early diagnosis allows early intervention, increases the quality of life of these individuals, and reduces the cost of health care.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government